Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.
Hardly for the first time recently, the company is making a pricey acquisition.
Hardly for the first time recently, the company is making a pricey acquisition.
BELLINGS Intelligence Score: 12
Why it matters
This acquisition is a routine corporate M&A transaction within the pharmaceutical sector and does not materially alter credit markets, underwriting standards, or systemic credit conditions.
Sources
The Motley Fool
Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.
Hardly for the first time recently, the company is making a pricey acquisition.